ReviewJournal of diabetes investigation2025
Circulating cell-free mitochondrial DNA in diabetes mellitus: Current insights and unexplored frontiers.
Review in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innovative mitochondria-based holistic 3PM approach to female health status: Facts and outlook.The EPMA journal · 2026Article
- Myosteatosis in type 1 diabetes: immunometabolic mechanisms, biomarkers, and therapeutic targets.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role and significance of circulating cell-free mitochondrial DNA (ccf-mtDNA)-small fragments of mitochondrial DNA present in plasma-are becoming increasingly clear in various diseases. The release of mtDNA into the plasma results from mitochondrial dysfunction, cell death, and NETosis, all of which are elevated in diabetes and its complications. Due to its resemblance to pathogenic DNA, mitochondrial DNA can activate several immunological pathways, leading to inflammation-a key factor in diabetes and its complications. Studies reveal a significant overlap between the immunological pathways involved in diabetes and those triggered by ccf-mtDNA. Thus, ccf-mtDNA may play a crucial role in the pathophysiology of diabetes and its complications, making it a potential diagnostic, prognostic, and therapeutic target. This review aims to summarize research findings on the role of ccf-mtDNA in diabetes, including gestational diabetes and related complications. Most studies have focused on type 2 diabetes, whereas research on ccf-mtDNA in other forms, including type 1 diabetes, remains limited. By synthesizing these insights, we seek to clarify the role of ccf-mtDNA in diabetes and identify gaps for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.